- Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Hainsworth, J.D., Spigel, D.R., Markus, T.M., Shipley, D., Thompson, D., Rotman, R., Dannaher, C., Greco, F.A. Clin. Lymphoma. Myeloma (2009)